SEHK:2096Pharmaceuticals
Simcere Pharmaceutical Group’s Valuation After SIM0709 Licensing Deal With Boehringer Ingelheim
Simcere Pharmaceutical Group (SEHK:2096) has drawn investor attention after announcing an exclusive licensing agreement with Boehringer Ingelheim for SIM0709, a TL1A/IL-23p19 bispecific antibody targeting inflammatory bowel disease.
See our latest analysis for Simcere Pharmaceutical Group.
The licensing news arrives after a mixed year in the market, with Simcere’s 1-year total shareholder return of 77.9% contrasting with a year to date share price return of 0.85% and a 90 day share price...